HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

terflavoxate

structure given in first source; RN given refers to HCl; RN for parent cpd not available 6/89

Also Known As:

Rec 15-2053

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrans: 130
    - Benzopyrans: 195
      - Chromones: 159
        Flavonoids: 9773
        Flavones: 446
        Flavoxate: 47
        terflavoxate: 2
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzopyrans: 195
      - Chromones: 159
        Flavonoids: 9773
        Flavones: 446
        Flavoxate: 47
        terflavoxate: 2

Related Diseases

1.	Overactive Urinary Bladder (Overactive Bladder) 02/01/1993 - "The antispasmodic activity of terflavoxate (CAS 86433-39-8), a flavone derivative with spasmolytic properties on the urinary tract, has been studied in vitro, in comparison to the most common drugs utilized in the therapy of overactive detrusor, namely flavoxate, oxybutynin, and terodiline. "
2.	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 04/01/1991 - "The antispasmodic effects of the flavone compounds flavoxate hydrochloride, 3-methylflavone carboxylic acid (MFCA), and REC 15/2053 (and in the case of the detrusor, oxybutynin), on the human detrusor, prostatic adenoma, prostatic capsule, and bladder neck, were studied by the in vitro isometric method. "

Related Drugs and Biologics

1.	Parasympatholytics (Antispasmodics)
2.	Flavoxate (Urispas)
3.	flavone
4.	oxybutynin (Tavor)
5.	Carboxylic Acids
6.	Capsules (Microcapsules)
7.	terodiline (TD 758)

Related Therapies and Procedures

1.	Therapeutics